Advertisement

ISCOMs and Immunostimulation with Viral Antigens

  • Stefan Höglund
  • Kristian Dalsgaard
  • Karin Lövgren
  • Bo Sundquist
  • Ab Osterhaus
  • Bror Morein
Chapter
Part of the Subcellular Biochemistry book series (SCBI, volume 15)

Abstract

With the dissection of microorganisms followed by biochemical and immunological characterization, antigens inducing protective immunity became recognized. Early attempts to use these isolated antigens as vaccines, i.e. subunit vaccines, showed that although immunogenic in situ as part of the microorganism, they were not immunogenic as purified antigens. Subsequent studies showed that the formation of antigen into defined multimeric forms such as protein micelles or into liposomes made them considerably more immunogenic. In a way, micelles and liposomes mimic a submicroscopic particle of a microorganism with several copies of surface antigens. By contrast, monomeric forms of antigens, e.g., envelope proteins of parainfluenza-3 virus or Semliki forest virus, not only had a low immunogenicity but had a specific suppressive effect on the immune response as well; this was shown when the monomers were given simultaneously with the same antigen in a micelle (Morein et al., 1982, 1983; Morein and Simons, 1985; Jennings, 1987).

Keywords

Viral Antigen Rabies Virus Measle Virus Bovine Viral Diarrhea Virus Bovine Leukemia Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Åkerblom, L., and Villacres, M., 1987, HIV iscoms: A vaccine model, in: Tenth Scandinavian Virus Symposium, Umeå, p. 72.Google Scholar
  2. Åkerblom, L., Höglund, S., Strömstedt, K., Osterhaus, A., and Morein, B., 1989, Formation and characterization of FeLV iscoms, Vaccine (in press).Google Scholar
  3. Alenius, A., Sundquist, B., and Carlsson, U., 1989, Protective effect of an iscom bovine diarrhea (BVD) virus vaccine against an experimental BVD virus infection in pregnant sheep, in preparation.Google Scholar
  4. Atanasin, P., 1973, Quantitative assay and potency test of anti-rabies serum and immunoglobulin, in: Laboratory Techniques in Rabies (M. Kaplan and H. Koprowski, eds.), pp. 314–318, World Health Organization, Geneva.Google Scholar
  5. Audibert, F., Jolivet, M., Chedid, L., Arnon, R., and Sela, M., 1982, Successful immunization with a totally synthetic diphtheria vaccine, Proc. Natl. Acad. Sci. USA 79:5042–5046.PubMedCrossRefGoogle Scholar
  6. Bangham, A. D., and Home, R. W., 1962, Action of saponin on biological cell membranes, Nature (London) 196:952–953.CrossRefGoogle Scholar
  7. Barnes, D. M., 1988, Obstacles to an AIDS vaccine, Science 240:719–721.PubMedCrossRefGoogle Scholar
  8. Bomford, R., 1980, The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect of delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse for Freund’s incomplete and complete adjuvants, Alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin, Clin. Exp. Immunol. 39:435–441.PubMedGoogle Scholar
  9. Brieskorn, C. H., and Briner, M., 1954, On the analysis of triterpenes. Colorimetric determination of the total content of triterpenoid acids in labiatae. Arch. Pharm. Detsch. Pharm. Ges. 287:429–432.CrossRefGoogle Scholar
  10. Dalsgaard, K., 1970, Thin layer Chromatographic fingerprinting of commercially available saponins, Dansk. Tidskr. Farm. 44:327–331.Google Scholar
  11. Dalsgaard, K., 1974, Saponin adjuvants. III. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in foot-and-mouth disease vaccines. Arch. Ges. Virusforsch. 44:243–254.PubMedCrossRefGoogle Scholar
  12. Dalsgaard, K., 1978, The application of the saponin adjuvant Quil A in foot-and-mouth disease vaccines, Bull. Off. Int. Epiz. 89:963–966.Google Scholar
  13. Dalsgaard, K., 1984, Assessment of the dose of the immunological adjuvant Quil A in mice and guinea pigs using sheep red blood cells as model antigens, Zbl. Vet. Med. B 31:718–720.CrossRefGoogle Scholar
  14. Dalsgaard, K., Jensen, M. H., and Sörensen, K. J., 1977, Saponin adjuvants. IV. Evaluation of the adjuvant Quil A in the vaccination of cattle against foot-and-mouth disease, Acta Vet. Scand. 18:349–360.PubMedGoogle Scholar
  15. DeVries, P., Van Binnendijk, R. S., Van der Marel, P., Van Wezel, A. L., Voorma, H. O., Sundquist, B., Uytdehaag, F. G. C. M., and Osterhaus, A. D. M. E., 1988a, Measles virus fusion protein presented in an immune-stimulating complex (Iscom) induces hemolysis-inhibiting and fusion-inhibiting antibodies, virus-specific T cells and protection in mice, J. Gen. Virol. 69:549–559.CrossRefGoogle Scholar
  16. De Vries, P., Uytdehaag, F. G. C. M., and Osterhaus, A. D. M. E., 1988b, Canine distemper virus (CDV) iscoms, but not measles virus iscoms, protect dogs against CDV infection, J. Gen. Virol. 69:2071–2083.PubMedCrossRefGoogle Scholar
  17. Dourmashkin, R. R., Dougherty, R. M., and Harris, R. J., 1962, Electronmicroscopic observations on Rous sarcoma virus and cell membranes, Nature (Lond.) 194:1116–1119.CrossRefGoogle Scholar
  18. Erlanger, B. F., 1980, The preparation of antigenic hapten-carrier conjugates; a survey, Methods Enzymol. 70:85–104.PubMedCrossRefGoogle Scholar
  19. Espinet, E. G., 1951, Nuevo tipo de vacuna antiaftosa a complejo glucovirico, Gac. Vet. 74:1–13.Google Scholar
  20. Ferdinand, F. J., Dorner, F., and Kurth, R., 1987, Perspectives of HIV vaccine developments, J. Virol. Methods 17:63–67.PubMedCrossRefGoogle Scholar
  21. Fohlman, J., Ilbäck, N. G., Friman, G., and Morein, B., 1989, Vaccination of BALB/c mice against enteroviral mediated myocarditis, Vaccine (submitted).Google Scholar
  22. Freund, J., 1956, The mode of action of immunological adjuvants, Adv. Tuberc. Res. 7:130–148.Google Scholar
  23. Gelderblom, H., Reupke, H., and Pauli, G., 1985, Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis, Lancet 2:1016–1017.PubMedCrossRefGoogle Scholar
  24. Gelderblom, H. R., Hausmann, E. H. S., Özel, M., Pauli, G., and Koch, M. A. K., 1987, Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins, Virology 156:171–176.PubMedCrossRefGoogle Scholar
  25. Glauert, A. M., Dingle, J. T., and Lucy, J. A., 1962, Action of saponin on biological cell membranes, Nature (Lond.) 196:953–955.CrossRefGoogle Scholar
  26. Hanatani, M., Nishifuji, K., Futai, M., and Tsuchia, T., 1984, Solubilization and reconstitution of membrane proteins of Escherichia coli using alkanoyl-N-methylglucamides, J. Biochem. 95:1349–1353.PubMedGoogle Scholar
  27. Hannant, D., Jessett, D. M. O. Neill, T., Sundquist, B., and Mumford, J. A., 1987, Nasopharyngeal, tracheobronchial, and systemic immune responses to vaccination and aerosol infection with equine influenzavirus (H3N8), in: Seventh Equine Infection Disease Conference, Kentucky.Google Scholar
  28. Helenius, A., and Simons, K., 1975, Solubilization of membranes by detergents, Biochim. Biophys. Acta. 415:29–80.PubMedCrossRefGoogle Scholar
  29. Helenius, A., and von Bornsdorf, C. H., 1976, Semliki Forest virus proteins. Preparation and characterization of spike complexes soluble in detergent-free medium, Biochim. Biophys. Acta 436:895–899.PubMedCrossRefGoogle Scholar
  30. Helenius, A., McCaslin, D. R., Fries, E., and Tanford, C., 1979, Properties of detergents, Methods Enzymol. 56:734–749.PubMedCrossRefGoogle Scholar
  31. Henderson, L. E., Sowder, R., Copeland, T. D., Oroszlan, S., Arthur, L. O., Robey, W. G., and Fischinger, P. J., 1987, Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III, J. Virol. 61:629–632.PubMedGoogle Scholar
  32. Hildreth, J. E. K., 1982, N-D-Gluco-N-methylalkanamide compounds, a new class of non-ionic detergents for membrane biochemistry, Biochem. J. 207:363–366.PubMedGoogle Scholar
  33. Höglund, S., Åkerblom, L., Gelderblom, H., Özel, M., 1986a, Characterization of HTLV-III iscom, in: Proceedings of the International Conference on AIDS (J. C. Gluckman, eds.), p. 13.Google Scholar
  34. Höglund, S., Morein, B., Sundquist, B., Gelderblom, H., and Özel, M., 1986b, Immunostimulating complex (iscom) of viral envelope, in: Proceedings of the International Congress of Electron Microscopy (T. Imura, S. Maruse, and T. Suzuki, eds.), Kyoto, Japan, pp. 3403–3404.Google Scholar
  35. Höglund, S., Özel, M., Åkerblom, L., Villacrez, M., Gelderblom, H., and Morein, B., 1989, A construct of HIV antigens: Structural and immunological analysis, submitted.Google Scholar
  36. Hoxie, J. A., Fitzharris, T. P., Youngbar, P. R., Matthews, D. M., Rackowski, J. L., and Radka, S. F., 1987, Nonrandom association of cellular antigens with HTLV-III virions, Hum. Immunol. 18:39–52.PubMedCrossRefGoogle Scholar
  37. Jennings, R., Pemberton, R. M., Smith, T. L., Amin, T., and Potter, C. W., 1987, Demonstration of an immunosuppressive action of detergent-disrupted influenzavirus on the antibody response to inactivated whole virus vaccine, J. Gen. Virol. 68:441–450.PubMedCrossRefGoogle Scholar
  38. Jones, P. D., Tha Hla, R., Morein, B., and Ada, G. L., 1988, Cellular immune response in the murine lung to local immunization with influenza A virus glycoproteins in micelles and iscoms, Scand. J. Immunol. 27:645–652.PubMedCrossRefGoogle Scholar
  39. Letvin, L., Daniel, M. D., Kiyotaki, M., Kannagi, M., Chalifoux, L. V., Seghal, P. K., Desrosiers, R. C., Arthur, L., and Allison, A. C., 1987, AIDS-like disease in macaque monkeys induced by simian immunodeficiency virus: A vaccine trial, Vaccine 87:209–213.Google Scholar
  40. Liljas, L., 1986, The structure of spherical viruses, Proc. Biophys. Mol. Biol. 48:1–36.CrossRefGoogle Scholar
  41. Lövgren, K., and Morein, B., 1988, The requirement of lipids for the formation of immunostimulating complexes (iscoms), Biotechnol. Appl. Biochem. 10:161–172.PubMedGoogle Scholar
  42. Lövgren, K., Lindmark, J., Pipkorn, R., and Morein, B., 1987, Antigenic presentation of small molecules and peptides conjugated to a preformed iscom as carrier, J. Immunol. Methods 98:137–143.PubMedCrossRefGoogle Scholar
  43. Lövgren, K., Uggla, A., and Morein, B., 1987b, A new approach to the preparation of a Tox-oplasma gondii membrane antigen for use in ELISA, J. Vet. Med. 34:274–282.CrossRefGoogle Scholar
  44. Lövgren, K., 1988, The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenzavirus immunostimulating complexes, Scand. J. Immunol. 27:241–245.PubMedCrossRefGoogle Scholar
  45. Lucy, J. A, and Glauert, A. M., 1964, Structure and assembly of macromolecular lipid complexes composed of globular micelles, J. Mol. Biol. 8:727–748.PubMedCrossRefGoogle Scholar
  46. Mäizels, R. M., Philipp, M., and Oglive, M. O., 1982, Molecules of the surface of parasitic nematodes as probes of the immune response in infection, Immunol. Rev. 61:109–136.PubMedCrossRefGoogle Scholar
  47. McEven, C. R., 1967, Tables for estimating sedimentation through linear concentration gradients of sucrose solution, Anal. Biochem. 20:114–149.CrossRefGoogle Scholar
  48. Merza, M. S., Linné, T., Höglund, S., Morein, B., Porteteile, D., and Burny, A., 1989, Bovine leukemia virus iscoms: Biochemical characterization, Vaccine.Google Scholar
  49. Modrow, S., Hahn, B., Shaw, G. M., Gallo, R. C., Wong-Stahl, F., and Wolf, H., 1987, Computerassisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions, J. Virol. 61:570–578.PubMedGoogle Scholar
  50. Morein, B., and Simons, K., 1985, Subunit vaccines against enveloped viruses: Virosomes, micelles and other protein complexes, Vaccine 3:83–93.PubMedCrossRefGoogle Scholar
  51. Morein, B., Helenius, A., Simons, K., Pettrson, R., Kääriäinen, L., and Schirrmacher, V., 1978, Effective subunit vaccines against enveloped animal virus, Nature (Lond.) 276:715–718.CrossRefGoogle Scholar
  52. Morein, B., Sundquist, B., Höglund, S., Helenius, A., and Simons, K., 1982, Protein micelles and virosomes from the surface glycoproteins of parainfluenza-3 virus, in: Protides of the Biological Fluids (H. Peeters, ed.), pp. 101–104, Pergamon Press, Oxford.Google Scholar
  53. Morein, B., Sharp, M., Sundquist, B., and Simons, K., 1983, Protein subunit vaccines of Parainfluenza type 3 virus: Immunogenic effect in lambs and mice, J. Gen. Virol. 64:1557–1569.PubMedCrossRefGoogle Scholar
  54. Morein, B., Sundquist, B., Höglund, S., Dalsgaard, K., and Osterhaus, A., 1984, Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses, Nature (Lond.) 308:457–460.CrossRefGoogle Scholar
  55. Morein, B., Merza, M., Höglund, S., and Osterhaus, A., 1986, An approach to retrovirus vaccines, in: Proceedings of the Retrovirus of Human AIDS and Related Animal Diseases; “Colloque des Cent Gardes” Paris, pp. 168-171, (L. Montagnier), Paris.Google Scholar
  56. Morein, B., Lövgren, K., Höglund, S., and Sundquist, B., 1987, The Iscom: An immunostimulating complex, Immunol. Today 8:333–338.CrossRefGoogle Scholar
  57. Morein, B., Elkström, J., and Lörgren, K., 1989a, Inclusion of non-amphipathic protein (BSA) into ISCOMS increased its immunogenicity, submitted for publication.Google Scholar
  58. Morein, B., Soos, T., Rusvai, M., McGwire, B. S., Bognar, K., and Belak, S., 1989b, Efficacy of immunostimulating complexes for controlling pseudorabies (Aujeszky’s disease)Google Scholar
  59. Morgan, A. J., Finerty, S., Lövgren, K., Scullion, F. T., and Morein, B., 1988b, Prevention of Epstein-Barr (EB) virus induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into iscoms, J. Gen. Virol. 69:2093–2096.PubMedCrossRefGoogle Scholar
  60. Moss, B., Fuerst, T. R., Flexner, C., and Hugin, A., 1988, Roles of vaccinia virus in the development of new vaccines, Vaccine 6:161–163.PubMedCrossRefGoogle Scholar
  61. Mumford, J. A., Cook, R. F., Hannant, D., Jesset, D. M., Wood, J. M., and Sundquist, B., 1986, The evaluation of antigen presentation methods and adjuvants for the enhancement of antigenicity and immunogenicity of equine influenza vaccines, in: Proceedings of the First International Veterinary Immunology Symposium, Guelph, Canada.Google Scholar
  62. Murray, K., 1988, Application of recombinant DNA techniques in the development of viral vaccines, Vaccine 6:164–174.PubMedCrossRefGoogle Scholar
  63. Newmark, P., 1988, Receding hopes of AIDS vaccines, Nature (Lond.) 33:p. 699.Google Scholar
  64. Osterhaus, A., 1988, Induction of anti-FeLV antibodies in cats with vaccinated virus and FeLV iscom.Google Scholar
  65. Osterhaus, A., Weijer, K., Uytdehaag, F., Jarrett, O., Sundquist, B., and Morein, B., 1985, Induction of protective immune response in cats by vaccination with feline leukemia virus iscom, J. Immunol. 135:591–596.PubMedGoogle Scholar
  66. Osterhaus, A. D. M. E., Sundquist, B., Morein, B., Steenis, G., and van Uytdehaag, F., 1986, Comparison of an experimental rabies iscom subunit vaccine with inactivated dog kidney cell vaccine, in: Proceedings of the First International Veterinary Immunology Symposium, Guelph, Canada.Google Scholar
  67. Osterhaus, A., Weijer, K., Uytdehaag, F., Knell, P., Jarrett, O., and Morein, B., 1987, Comparison of serological responses in cats vaccinated with two different FeLV vaccine preparations, Vet. Rec. 121:260.PubMedCrossRefGoogle Scholar
  68. Özel, M., Pauli, G., and Gelderblom, H., 1988, The organization of the envelope projections on the surface of HIV, Arch. Virol.Google Scholar
  69. Özel, M., Höglund, S., Gelderblom, H., and Morein, B., 1989, The construct of iscom, in preparation.Google Scholar
  70. Palfreyman, J. W., Aitcheson, T. C., and Taylor, P., 1984, Guidelines for the production of polypeptide specific antisera using small synthetic oligopeptides as immunogens, J. Immunol. Methods 75:383–393.PubMedCrossRefGoogle Scholar
  71. Pyle, S. W., Morein, B., Bess, J., Nara, P. L., Nigida, S. M., Lerche, N., Fischinger, P., Arthur, L., 1989, Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-1) or the HVI-1 external envelope glycoprotein (gp 120) Vaccine (submitted).Google Scholar
  72. Seligman, E. B., 1978, Laboratory Techniques in Rabies, 3rd ed., World Health Organization, Geneva.Google Scholar
  73. Skoglund, U., Andersson, K., Strandberg, B., and Daneholt, B., 1986, Three-dimentional structure of a specific pre-messenger RNP particle established by electron microscope tomography, Nature 319:560–564.PubMedCrossRefGoogle Scholar
  74. Speijers, G. J. A., Danse, L. H. J. C., Beuvery, J. J. T. W., Strik, A., and Vos, J. G., 1987, Local reactions of the Saponin Quil A and a Quil A containing iscom measles vaccine after intramuscular injection of rats: A comparison with the effect of DPT-polio vaccine, Fund. Appl. Toxicol. 10:425–430.CrossRefGoogle Scholar
  75. Sundquist, B., Dalsgaard, K., and Morein, B., 1983, Assay of detergents by rocket electrophoresis in agarose gels containing red blood cells: “Rocket hemolysis,” Biochim. Biophys. Res. Commun. 114:699–704.CrossRefGoogle Scholar
  76. Sundquist, B., Lövgren, K., Höglund, S., and Morein, B., 1988a, Influenzavirus iscoms: Biochemical characterization, Vaccine 6:44–48.PubMedCrossRefGoogle Scholar
  77. Sundquist, B., Morein, B., and Jonsson, K., 1988b, Registration file for a horse influenza virus vaccine in Sweden.Google Scholar
  78. Tanford, C., and Reynolds, J. A., 1976, Characterization of membrane proteins in detergent solutions, Biochim. Biophys. Acta. 457:133–170.PubMedCrossRefGoogle Scholar
  79. Trudel, M., Nadon, F., Seguin, C., Simard, C., and Lussier, G., 1988, Experimental polyvalent iscom subunit vaccine based on the fusion protein induces antibodies that neutralize human and bovine respiratory syncytial virus, Vaccine. Google Scholar
  80. Uggla, A., Araujo, F. G., Lunden, A., Lövgren, K., Remington, J. S., and Morein, B., 1989, Immunizing effects in mice of two Toxoplasma gondii preparations, J. Vet. Med. in press.Google Scholar
  81. Uytdehaag, F. G. C. M., Osterhaus, A. D. M. E., Loggen, H. G., Bakker, R. H. J., Van Aasten, J. A. A. M., Kreeftenberg, J. G., Van der Marel, P., and Van Steenis, G., 1983, Induction of antigen-specific antibody response in human peripheral blood lymphocytes in vitro by a dog kidney cell vaccine against rabies virus (DKCV), J. Immunol. 131:1234–1239.PubMedGoogle Scholar
  82. Varsanyi, T. M., Morein, B., Löve, A., and Norrby, E., 1987, Protection against lethal Measles virus infection in mice by immune-stimulating complexes containing the hemagglutinin or fusion protein, J. Virol. 61:3896–3901.PubMedGoogle Scholar
  83. Wahren, B., Nordlund, S., Åkersson, A., Sundquist, B., and Morein, B., 1987, Monocyte and iscom enhancement of cell-mediated response to cytomegalovirus, Med. Microbiol. Immunol. 176:13–17.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Stefan Höglund
    • 1
  • Kristian Dalsgaard
    • 2
  • Karin Lövgren
    • 3
  • Bo Sundquist
    • 4
  • Ab Osterhaus
    • 5
  • Bror Morein
    • 3
  1. 1.Institute of Biochemistry, Biomedical CenterUppsalaSweden
  2. 2.State Veterinary Institute of Virus ResearchLindholm, KalvehaveDenmark
  3. 3.Department of Virology, Biomedical CenterThe National Veterinary InstituteUppsalaSweden
  4. 4.Division of Vaccine ResearchThe National Veterinary InstituteUppsalaSweden
  5. 5.National Institute of Public Health and Environmental HygieneBilthovenThe Netherlands

Personalised recommendations